PriceTargets.com logo

Cronos Group - CRON Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $2.83
  • Forecasted Upside: 14.25%
  • Number of Analysts: 3
  • Breakdown:
  • 1 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.48 As of 04/24/2024 01:00 AM ET
▲ +0.01 (0.40%)

This chart shows the closing price for CRON by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cronos Group Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRON and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRON

Analyst Price Target is $2.83
▲ +14.25% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Cronos Group in the last 3 months. The average price target is $2.83, with a high forecast of $3.00 and a low forecast of $2.50. The average price target represents a 14.25% upside from the last price of $2.48.

This chart shows the closing price for CRON for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 3 polled investment analysts is to hold stock in Cronos Group. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/8/2024Bank of AmericaBoost TargetUnderperform ➝ Underperform$2.00 ➝ $2.50Low
12/28/2023Bank of AmericaBoost TargetUnderperform ➝ Underperform$1.78 ➝ $2.00Low
11/9/2023CIBCBoost TargetOutperform$2.75 ➝ $3.00Low
5/18/2023Roth CapitalReiterated RatingBuyLow
5/15/2023BarclaysLower Target$3.50 ➝ $3.00Low
3/1/2023Raymond JamesLower TargetOutperform$7.00 ➝ $3.00Low
11/8/2022Canaccord Genuity GroupLower TargetC$5.00 ➝ C$4.75Low
11/1/2022Sanford C. BernsteinInitiated CoverageMarket Perform$3.00Low
9/30/2022BarclaysLower TargetEqual Weight$5.00 ➝ $3.50Low
7/29/2022Raymond JamesReiterated RatingBuy$7.00Low
7/28/2022Canaccord Genuity GroupUpgradeHold ➝ BuyLow
5/11/2022Canaccord Genuity GroupUpgradeSell ➝ HoldC$4.50High
5/11/2022CIBCUpgradeNeutral ➝ Sector OutperformHigh
5/9/2022Raymond JamesBoost TargetOutperform$5.00 ➝ $6.00High
3/22/2022BarclaysUpgradeUnderweight ➝ Equal Weight$5.00Medium
3/7/2022Piper SandlerLower TargetNeutral$4.00 ➝ $3.00High
3/2/2022Raymond JamesSet TargetOutperform$5.00Low
2/22/2022Raymond JamesLower TargetOutperform$11.00 ➝ $5.00Low
2/22/2022Canaccord Genuity GroupLower TargetSell$7.00 ➝ $4.25Medium
2/22/2022Stifel NicolausLower Target$6.50 ➝ $4.00Medium
2/22/2022Piper SandlerLower TargetNeutral$7.00 ➝ $4.00Medium
1/27/2022Jefferies Financial GroupUpgradeUnderperform ➝ Hold$5.54 ➝ $3.24Medium
12/17/2021Raymond JamesReiterated RatingOutperform$14.00Low
11/18/2021Bank of AmericaInitiated CoverageUnderperform$5.00Medium
11/18/2021BarclaysInitiated CoverageUnderweight$5.50High
10/21/2021Raymond JamesSet TargetOutperform$11.00Low
8/24/2021Raymond JamesSet TargetOutperform$11.00Medium
8/9/2021Raymond JamesSet TargetOutperform$11.00Medium
6/15/2021Raymond JamesSet TargetOutperform$11.00Low
6/7/2021Raymond JamesReiterated RatingOutperform$11.00Low
5/10/2021Raymond JamesSet TargetOutperform$11.00Low
4/28/2021Bank of AmericaInitiated CoverageUnderperformHigh
4/26/2021Raymond JamesSet TargetOutperform$11.00Low
3/1/2021Raymond JamesSet TargetOutperform$11.00Low
2/22/2021CIBCDowngradeOutperform ➝ Neutral$8.00 ➝ $12.50Low
2/4/2021Stifel NicolausReiterated RatingHold$8.00Low
11/17/2020Raymond JamesBoost TargetOutperform$10.00 ➝ $11.00Low
11/16/2020Jefferies Financial GroupLower TargetUnderperform$5.60 ➝ $5.00Low
11/6/2020Raymond JamesSet TargetOutperform$10.00High
9/14/2020Raymond JamesSet TargetOutperform$10.00High
9/8/2020Raymond JamesSet TargetOutperform$10.00Medium
9/2/2020Raymond JamesSet TargetOutperform$10.00High
8/18/2020Raymond JamesSet TargetOutperform$10.00Low
8/7/2020Raymond JamesSet TargetOutperform$10.00N/A
6/23/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$6.50 ➝ $13.52High
5/22/2020Raymond JamesSet TargetMarket Perform$6.50Medium
5/11/2020Pi FinancialReiterated RatingHold$8.50Medium
5/11/2020Raymond JamesSet TargetMarket Perform$6.50Low
5/11/2020Stifel NicolausLower TargetHold$8.00 ➝ $7.50High
4/27/2020Raymond JamesDowngradeOutperform ➝ Market Perform$10.50 ➝ $6.50High
4/19/2020Piper SandlerDowngradeOverweight ➝ NeutralMedium
4/13/2020Piper SandlerDowngradeOverweight ➝ Neutral$12.00 ➝ $7.00High
4/2/2020Bank of AmericaDowngradeBuy ➝ Neutral$9.00Low
3/4/2020MKM PartnersUpgradeNeutral ➝ Buy$12.00 ➝ $11.00High
3/3/2020Stifel NicolausDowngradeBuy ➝ Hold$12.00 ➝ $8.00High
12/21/2019Raymond JamesSet TargetOutperform$12.00Low
11/13/2019CIBCReiterated RatingBuy$17.00High
10/22/2019Piper Sandler CompaniesLower TargetOverweight$18.00 ➝ $12.00Low
10/18/2019Stifel NicolausUpgradeHold ➝ Buy$16.50 ➝ $14.00High
9/19/2019MKM PartnersInitiated CoverageNeutral$14.00Low
9/5/2019BMO Capital MarketsUpgradeUnderperform ➝ Market PerformHigh
8/12/2019Piper Sandler CompaniesInitiated CoverageOverweight ➝ Overweight$18.00Medium
8/9/2019BMO Capital MarketsReiterated RatingSellMedium
8/9/2019Bank of AmericaBoost TargetBuy$20.00 ➝ $26.00Low
6/28/2019Consumer EdgeInitiated CoverageEqual Weight ➝ Equal WeightLow
6/5/2019Stifel NicolausInitiated CoverageHold ➝ HoldLow
6/5/2019Bank of AmericaUpgradeUnderperform ➝ Buy$13.00 ➝ $20.00High
(Data available from 4/25/2019 forward)

News Sentiment Rating

0.69 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/27/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/27/2023
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/26/2023
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
12/26/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/25/2024
  • 5 very positive mentions
  • 9 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
2/24/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2024
  • 19 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
Mentions as of
4/24/2024

Current Sentiment

  • 19 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Cronos Group logo
Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.
Read More

Today's Range

Now: $2.48
Low: $2.43
High: $2.55

50 Day Range

MA: $2.35
Low: $1.93
High: $2.88

52 Week Range

Now: $2.48
Low: $1.64
High: $2.99

Volume

2,519,835 shs

Average Volume

4,015,049 shs

Market Capitalization

$947.38 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.17

Frequently Asked Questions

What sell-side analysts currently cover shares of Cronos Group?

The following equities research analysts have issued stock ratings on Cronos Group in the last twelve months: Bank of America Co., Barclays PLC, CIBC, and Roth Capital.
View the latest analyst ratings for CRON.

What is the current price target for Cronos Group?

3 Wall Street analysts have set twelve-month price targets for Cronos Group in the last year. Their average twelve-month price target is $2.83, suggesting a possible upside of 14.2%. Barclays PLC has the highest price target set, predicting CRON will reach $3.00 in the next twelve months. Bank of America Co. has the lowest price target set, forecasting a price of $2.50 for Cronos Group in the next year.
View the latest price targets for CRON.

What is the current consensus analyst rating for Cronos Group?

Cronos Group currently has 1 sell rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRON, but not buy more shares or sell existing shares.
View the latest ratings for CRON.

What other companies compete with Cronos Group?

Other companies that are similar to Cronos Group include USANA Health Sciences, Canopy Growth, Mind Medicine (MindMed), biote and Aurora Cannabis. Learn More about companies similar to Cronos Group.

How do I contact Cronos Group's investor relations team?

Cronos Group's physical mailing address is 111 PETER STREET SUITE 300, TORONTO A6, M5V 2G9. The company's listed phone number is (416) 504-0004 and its investor relations email address is [email protected]. The official website for Cronos Group is www.thecronosgroup.com. Learn More about contacing Cronos Group investor relations.